Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
A study showed that Cyramza with paclitaxel improved survival in gastric cancer over paclitaxel alone.
Treatment Efficacy in Metastatic Esophageal, Gastric, or Gastroesophageal Cancer According to Expression of ERCC1
The biomarker ERCC1 is of interest for predicting sensitivity to platinum-based chemo, but a recent study in the Journal of Clinical Oncology... Read More
Guardant’s blood test tracks microsatellite instability status on par with tissue biopsy in new study
In a trial involving 949 patients with 40 tumor types, including gastric cancer, a blood test from Guardant Health was as good... Read More
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Researchers evaluated the addition of the AKT inhibitor ipatasertib to mFOLFOX6 for patients with gastric cancer.
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends
A review of evolving trends in third line treatment of advanced gastric cancer shows sequential treatment approaches benefit a growing minority of... Read More
Outlooks on Epstein-Barr virus associated gastric cancer
New research finds Epstein-Barr virus associated gastric cancer (EBVaGC) associated gastric cancer, which comprises approximately 10% of gastric cancer, is a promising biomarker.... Read More